ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Alseres Pharmaceuticals Announces FDA Clearance To Increase Dose Level In Cethrin(R) Phase I/IIa Clinical Trial For Acute Spinal Cord Injury
Alseres
Pharmaceuticals, Inc. (Nasdaq: ALSE) formerly Boston Life Sciences, Inc.
(BLSI) announced today that the U.S. Food and Drug Administration (FDA) has
authorized an increase in the dose level of Cethrin to 9mg in the Company's
ongoing Phase I/IIa clinical study for the treatment of acute spinal cord
injury (SCI). In April, the Company announced that dosing at the 9mg level
had begun in Canadian trial sites under a Canadian Clinical Trial
Application.
Patients with acute SCI are enrolled in the open label study at sites
across Canada and the United States. Previous dose groups included in the
study were 0.3mg, 1mg, 3mg and 6mg. All patients enrolled in the trial have
complete spinal cord injuries, referred to as "ASIA A" as assessed under
the American Spinal Injury Association (ASIA) rating scale. That means each
study participant suffered a complete thoracic or cervical injury (i.e.
having no sensory or motor function below the level of the SCI). ASIA
grades are designated from A through E, with 'A' designating complete SCI
and 'E' being normal. Grades 'B' through 'D' designate increasing levels of
motor and sensory improvements.
Interim results reported to date on the thirty-seven patients enrolled
in the first four dose groups, indicate that Cethrin is well tolerated. The
interim efficacy analysis in these groups indicates that Cethrin treated
patients experience a frequency of post-treatment conversions from ASIA A
to ASIA B or greater which is four times the conversion rate seen with the
standard of care reported in the literature (6.7%, Burns, J. Neurotrauma,
2003). When subgroups of patients treated with Cethrin are analyzed,
patients with cervical injuries exhibit a more pronounced response compared
to patients with thoracic injuries, showing a conversion rate that is six
to seven times greater than the full patient group treated with the
standard of care reported in the publication above. In patients with
cervical injuries, the interim efficacy data also suggest that the response
rate observed is dose dependent at the doses tested to date.
"We are pleased that the FDA has authorized the use of the 9mg dose of
Cethrin and allowed the continuation of this trial at the Company's U.S.
clinical trial sites," commented Mark Hurtt, Alseres' Chief Medical
Officer. "We believe that this action will further support our efforts to
design a well-controlled Phase IIb/III clinical study in the coming
months."
By the end of the third quarter, the Company plans to meet with
regulatory authorities to review its plans for its proposed Phase IIb/III
clinical study. If agreement with regulatory authorities can be reached in
a timely manner, the Company expects to begin the Phase IIb/III clinical
study by the end of the year or early 2008.
About Cethrin
Cethrin is a recombinant protein drug intended to facilitate the
re-growth of axons during the critical period immediately after a major
injury to the spinal cord. Following an SCI, about two-thirds of patients
undergo decompression/stabilization surgery. During surgery, Cethrin is
delivered by a single application to the injured region of the spinal cord.
Cethrin has been designated as an Orphan Drug by the FDA.
About Alseres Pharmaceuticals, Inc.
Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the clinical
development of diagnostic and therapeutic products for central nervous
system (CNS) disorders. Cethrin(R), a recombinant-protein-based drug
designed to promote nerve repair after acute spinal cord injury, has
reported positive interim results in a Phase I/IIa clinical trial.
ALTROPANE(R), a molecular imaging agent, is in Phase III clinical trials
for the diagnosis of Parkinson's Disease (PD). The company's research and
pre-clinical CNS programs include Inosine for the treatment of spinal cord
injury and stroke, a DAT blocker for the treatment of Parkinson's disease,
and a second generation technetium-based molecular imaging agent for PD and
ADHD. Alseres' current research collaborations include Harvard Medical
School and Children's Hospital Boston.
Safe harbor
The foregoing release contains certain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Forward- looking statements include statements regarding Alseres
Pharmaceuticals, Inc. future expectations, beliefs, intentions, goals,
strategies, plans or prospects regarding the future, including the
development and commercialization of ALTROPANE and Cethrin, the prospects
of the Company's CNS therapeutics program, the Company's strategies to
develop and commercialize axon regeneration technologies and the breadth of
the Company's technologies and intellectual property portfolio.
Forward-looking statements can be identified by terminology such as
"anticipate," "believe," "could," "could increase the likelihood,"
"estimate," "expect," "intend," "is planned," "may," "should," "will,"
"will enable," "would be expected," "look forward," "may provide," "would"
or similar terms, variations of such terms or the negative of those terms.
Such forward-looking statements involve known and unknown risks,
uncertainties and other factors including those risks, uncertainties and
factors referred to in the Company's Quarterly Report on Form 10-Q for the
quarter ended March 31, 2007 filed with the Securities and Exchange
Commission under the section "Risk Factors," as well as other documents
that may be filed by Alseres Pharmaceuticals, Inc. from time to time with
the Securities and Exchange Commission. As a result of such risks,
uncertainties and factors, the Company's actual results may differ
materially from any future results, performance or achievements discussed
in or implied by the forward-looking statements contained herein. Alseres
Pharmaceuticals, Inc. is providing the information in this press release as
of this date and assumes no obligations to update the information in this
press release.
Alseres Pharmaceuticals, Inc.
http://www.bostonlifesciences.com
Alseres Pharmaceuticals anunþã FDA Clearance-ul pentru a creºte doza la nivel Cethrin (R) de fazã I / IIa studiu clinic de mãduva spinãrii Leziuni acute - Alseres Pharmaceuticals Announces FDA Clearance To Increase Dose Level In Cethrin(R) Phase I/IIa Clinical Trial For Acute Spinal Cord Injury - articole medicale engleza - startsanatate